Bionano Genomics Earnings Call Transcripts
Fiscal Year 2025
-
Q4 and full year 2025 revenue declined year-over-year, but gross margin and operating efficiency improved significantly. Strategic focus on high-volume routine users and software integration drove more predictable, profitable revenue, with 2026 guidance projecting 5%-16% growth.
-
Q3 2025 saw 21% revenue growth, record flow cell sales, and a 46% non-GAAP gross margin. Consumables and software drove product mix gains, while a $10M public offering extended the cash runway. Full-year revenue guidance of $26–30M was reiterated.
-
Optical genome mapping is gaining traction as a complementary tool to sequencing, with strong adoption in cytogenetic labs for cancer and genetic disease analysis. Consumables drive revenue growth, while software offers high margins. The company expects double-digit growth, with barriers to adoption largely overcome and significant market potential ahead.
-
Optical genome mapping and AI-driven software are transforming pathology by replacing outdated workflows, improving accuracy, and expanding clinical utility. Strategic focus on core customers and cost control has led to revenue growth, higher margins, and strong adoption, with expanded reimbursement and positive financial outlook for 2025.
-
Q2 2025 revenue was $6.7M, down 13% year-over-year, but consumables and software sales grew 16%. Non-GAAP gross margin rose to 52%, and operating expenses dropped 53%. Full-year revenue guidance is $26–$30M, with raised OGM system installation targets.
-
Optical genome mapping is consolidating legacy cytogenetic workflows, driving faster, more accurate diagnostics and expanding into clinical, pharma, and global markets. Strategic focus on customer support, margin improvement, and reimbursement is expected to fuel growth and profitability.
-
The meeting covered director elections, executive compensation, auditor ratification, and a share issuance proposal, all of which were approved by stockholder vote. No questions were raised by stockholders, and final results will be filed with the SEC.
-
Q1 2025 saw a 26% revenue decline due to discontinued services, but gross margin rose to 46% and operating expenses dropped sharply. Strategic focus on high-utilization customers stabilized core revenue, with full-year guidance reflecting global trade headwinds.
-
Stockholders approved the issuance of new shares related to warrant exercises and authorized a reverse stock split at a ratio between 1-for-25 and 1-for-75, both at the Board's discretion. No questions were raised by attendees.
Fiscal Year 2024
-
Q4 2024 revenue fell 24% year-over-year to $8.2M, but gross margin improved to 42%. Full-year product revenue grew 1%, with strong consumables and software sales. 2025 revenue is guided at $29M–$32M, with a focus on routine-use customers and extended cash runway into Q1 2026.
-
Q3 2024 revenue fell 35% year-over-year due to discontinued services and a strategic shift, but consumables sales grew 27% and cost reductions improved cash burn. Guidance for Q4 is $6–$7 million revenue, with further expense cuts and growth in consumables expected as reimbursement initiatives take effect.
-
A major business transformation is underway, shifting focus to recurring revenue from the installed base and reducing operating expenses to achieve cash flow breakeven. Product innovation and new partnerships are driving adoption, with revised revenue guidance reflecting a more focused strategy.
-
Stratys, a high-throughput optical genome mapping system, is driving new customer adoption and replacing traditional cytogenetic methods with faster, more accurate diagnostics. Market expansion is supported by clinical guidelines, new reimbursement codes, and growing pharma demand, despite near-term financial headwinds.
-
Q2 2024 revenue fell 10% year-over-year to $7.8M, mainly due to discontinued services and China underperformance. Cost reductions improved margins, and the AMA's CPT code approval for OGM is expected to drive future adoption and reimbursement.
-
The meeting featured a transition in board leadership, approval of all shareholder proposals including director elections and executive compensation, and ratification of the auditor. No questions were raised by stockholders during the Q&A.